Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases
There are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other thrombotic events. One key missing component of the risk-benefit analysis of using such vaccines is the risk of these severe thrombotic events following COVID-19.
Using a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of CVT... Expand abstract
- Publication status:
(Version of record, 601.6KB)
- Publisher copy:
- Copyright holder:
- Taquet et al.
- Copyright date:
- Rights statement:
- ©2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
If you are the owner of this record, you can report an update to it here: Report update to this record